Edition:
United States

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

11.41EUR
15 Dec 2017
Change (% chg)

€0.12 (+1.02%)
Prev Close
€11.30
Open
€11.65
Day's High
€11.70
Day's Low
€11.32
Volume
203,522
Avg. Vol
111,849
52-wk High
€14.08
52-wk Low
€9.40

Latest Key Developments (Source: Significant Developments)

Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests
Monday, 4 Dec 2017 01:00am EST 

Dec 4 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS AND AMGEN <<>> SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS.BIOCARTIS -WILL PURSUE A PREMARKET APPROVAL FOR IDYLLA KRAS MUTATION TEST AND IDYLLA NRAS-BRAF MUTATION TEST WITH FDA​.‍AMGEN WILL PROVIDE FINANCIAL AND OPERATIONAL SUPPORT TO BIOCARTIS FOR PMA PROCESS​.‍AIM OF AGREEMENT IS TO REGISTER IDYLLA RAS BIOMARKER TESTS WITH US FDA AS COMPANION DIAGNOSTIC TEST FOR AMGEN'S DRUG VECTIBIX(PANITUMUMAB).​.  Full Article

Bookrunner says Biocartis Group deal upsized to 80 mln euros From 60 mln euros base deal size‍​
Tuesday, 28 Nov 2017 02:13pm EST 

Nov 28 (Reuters) - :BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS DEAL UPSIZED TO 80 MILLION EUROS FROM 60 MILLION EUROS BASE DEAL SIZE‍​.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS BOOKS ARE OVERSUBSCRIBED ON THE 80 MILLION EUROS DEAL SIZE.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS PRICE GUIDANCE OF 12.50 EUROS PER SHARE.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS BOOKS CLOSE AT 1830 UK TIME.  Full Article

Biocartis Share Offering Of Up To About 8.9 mln Shares ‍​- bookrunner
Tuesday, 28 Nov 2017 10:45am EST 

Nov 28 (Reuters) - Biocartis Group Nv's Bookrunner: :SAYS OFFERING OF UP TO ABOUT 8.9 MILLION SHARES ‍​.SAYS OFFERING DEAL SIZE ABOUT 60 MILLION EUROS‍​.  Full Article

Biocartis Launches Equity Placement
Tuesday, 28 Nov 2017 10:30am EST 

Nov 28 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT.‍EQUITY OFFERING TO RAISE AN AMOUNT OF APPROXIMATELY EUR 60 MILLION BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING​.‍POSSIBILITY TO INCREASE SIZE OF OFFERING TO UP TO 8,933,950 NEW SHARES IN TOTAL​.‍BOOKBUILDING PROCEDURE WILL COMMENCE IMMEDIATELY​.‍TRADING IN BIOCARTIS SHARES ON EURONEXT BRUSSELS WILL BE SUSPENDED DURING BOOKBUILDING PERIOD​.‍J.P. MORGAN, DEGROOF PETERCAM, KBC SECURITIES AND KEMPEN ARE ACTING AS JOINT BOOKRUNNERS IN OFFERING​.‍ENVISAGES USING NET PROCEEDS TO FUND EXPANSION OF IDYLLA TEST MENU AND APPLICATIONS​.‍TRADING IN STOCK IS EXPECTED TO RESUME FOLLOWING PUBLICATION OF RESULTS OF OFFERING​.  Full Article

Biocartis Group sees ‍2017 guidance reiterated
Thursday, 16 Nov 2017 01:00am EST 

Nov 16 (Reuters) - BIOCARTIS GROUP NV ::SEES ‍2017 GUIDANCE REITERATED​.‍CASH POSITION AT END OF Q3 2017 AMOUNTED TO APPROXIMATELY EUR 56 MILLION (UNAUDITED FIGURE)​.  Full Article

Genomic Health and Biocartis announce agreement to develop a breast cancer test
Wednesday, 13 Sep 2017 01:00am EDT 

Sept 13 (Reuters) - BIOCARTIS GROUP NV ::‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​.‍EXCLUSIVE AGREEMENT TO DEVELOP AN IVD VERSION OF ONCOTYPE DX BREAST RECURRENCE SCORE TEST ON BIOCARTIS' IDYLLA PLATFORM​.‍ONCOTYPE DX BREAST RECURRENCE SCORE TEST PLANNED FOR LAUNCH IN EUROPE BEGINNING WITH FRANCE AND GERMANY IN 2019​.‍AS PART OF AGREEMENT, GENOMIC HEALTH WILL MAKE A PAYMENT OF APPROXIMATELY $3.3 MILLION TO BIOCARTIS, WHICH IS EXPECTED TO BE EXPENSED IN Q3 OF 2017​.‍GENOMIC HEALTH CONTINUES TO EXPECT TO BE PROFITABLE FOR FULL YEAR 2017, EXCLUDING THESE TRANSACTION COSTS​.‍UPON COMMERCIALIZATION, GENOMIC HEALTH WILL MAKE ROYALTY PAYMENTS TO BIOCARTIS BASED ON NET SALES OF IVD TESTS DEVELOPED ON BIOCARTIS' IDYLLA PLATFORM​.  Full Article

Biocartis H1 total operating income up at 6.8 million euros
Thursday, 7 Sep 2017 01:01am EDT 

Sept 7 (Reuters) - BIOCARTIS GROUP NV ::H1 RESULTS‍​.H1 TOTAL OPERATING INCOME EUR 7.0 MILLION VERSUS EUR 6.8 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS OF EUR 59.0M AS PER END H1 2017‍​.H1 TOTAL REVENUE EUR 5.9 MILLION VERSUS EUR 6.1 MILLION YEAR AGO.H1 NET LOSS EUR 24.0 MILLION VERSUS LOSS OF EUR 23.8 MILLION YEAR AGO.OPERATIONAL LOSS EUR 23.7 MILLION VERSUS LOSS OF EUR 24.0 MILLION YEAR AGO.GUIDANCE FOR 2017 FY REITERATED.EXPECTED TEST MENU NEWS FLOW IN H2 2017: CE-MARKING IDYLLA CTKRAS MUTATION TEST AND IDYLLA CTNRAS-BRAF MUTATION TEST.EXPECTED TEST MENU NEWS FLOW IN H2 2017: LAUNCH OF A LIQUID BIOPSY VERSION OF IDYLLA CTEGFR MUTATION ASSAY (RUO).  Full Article

Biocartis' Idylla respiratory panel receives clearance by FDA
Tuesday, 5 Sep 2017 01:27am EDT 

Sept 5 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: IDYLLA(TM) RESPIRATORY (IFV-RSV) PANEL RECEIVES 510(K) CLEARANCE BY US FDA.  Full Article

Biocartis' Idylla Instrument and Idylla Console exempt from FDA 510(k) notification requirements
Wednesday, 12 Jul 2017 01:00am EDT 

July 12 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS' IDYLLA(TM) INSTRUMENT AND IDYLLA(TM) CONSOLE EXEMPT FROM US FDA 510(K) NOTIFICATION REQUIREMENTS.‍ALL OTHER US 510(K) REQUIREMENTS REMAIN IN EFFECT​.‍CAN NOW WITHDRAW PENDING 510(K) SUBMISSION FOR IDYLLA(TM) INSTRUMENT AND IDYLLA(TM) CONSOLE​.BIOCARTIS - ‍EXEMPTION DOES NOT CHANGE ONGOING UNDERTAKING OF BIOCARTIS AND JANSSEN DIAGNOSTICS TO OBTAIN 510(K) CLEARANCE FOR JANSSEN IDYLLA RESPIRATORY (IFV-RSV) PANEL TEST​.  Full Article

Biocartis Group launches CE-marked IVD NRAS test for colorectal cancer
Tuesday, 23 May 2017 01:00am EDT 

May 23 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES CE-MARKED IVD NRAS TEST FOR COLORECTAL CANCER.  Full Article

BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests

* BIOCARTIS AND AMGEN SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS